A childhood cancer diagnosis can turn an ordinary family routine into a calendar of scans, infusions, hospital visits and long stretches of uncertainty. In British Columbia, Hyundai Canada’s Hope on Wheels program is adding fresh financial support to that fight, committing $350,000 in the province while linking the donation to a much larger national effort.
The B.C. commitment combines direct support for BC Children’s Hospital with a research grant aimed at hard-to-treat childhood bone cancers. It also arrives as Hyundai Auto Canada and its dealer network push their 2026 pediatric cancer commitment beyond $4.1 million, pairing hospital funding with clinical-trial support, research grants and family assistance across the country.
A B.C. Commitment Split Between Care and Research
Hyundai Hope on Wheels’ latest British Columbia commitment is best understood as two connected investments rather than a single cheque to one institution. Hyundai Canada and its dealer network are providing $100,000 to BC Children’s Hospital, while another $250,000 is being directed through the C17 Council to support pediatric cancer research in Vancouver. Together, those contributions total $350,000 in B.C. The announcement was made during the program’s 2026 cross-country tour, with a Handprint Ceremony held at Murray Hyundai White Rock for children and families connected to BC Children’s Hospital.
That distinction matters because the money is meant to work on two fronts at once. The hospital contribution supports the care environment surrounding children and families, while the research award targets questions that could shape future treatment. Hyundai describes the B.C. funding as one piece of a national 2026 commitment exceeding $4.1 million for pediatric cancer care, research and family-support programs. In other words, the local event is part of a broader funding model rather than an isolated corporate donation.
The Openshaw Twins Put a Human Face on the Numbers
For the Openshaw family, childhood cancer arrived twice. Weston Openshaw was two years old when he was diagnosed with acute lymphoblastic leukemia. Roughly four months later, his identical twin brother Bennett received the same diagnosis. The two boys were treated by the oncology team at BC Children’s Hospital at the same time, an unusual situation that the hospital had not previously encountered with twins. Their story has since been shared publicly through hospital and community events, including appearances as patient ambassadors.
Now seven, Weston and Bennett are cancer-free and known affectionately as the “Twincredible” ambassadors. Their presence at Hyundai’s 2026 event gives the funding a scale that statistics alone cannot. A six-figure grant can sound abstract until it is connected to the years a family spends navigating chemotherapy, appointments and uncertainty. The twins’ recovery also illustrates why pediatric oncology funding often spans more than treatment itself: research, precision medicine, psychosocial support and survivorship services all shape what life looks like during and after cancer.
Why BC Children’s Hospital Is Central to Pediatric Cancer Care
About 130 children in British Columbia are diagnosed with cancer each year, according to BC Children’s Hospital Foundation. The hospital plays a uniquely important role because every child diagnosed with cancer in the province has a treatment plan developed by its pediatric oncology experts. That makes donor-funded support especially consequential: even relatively rare diseases can create a province-wide care burden when highly specialized expertise is concentrated at a pediatric centre and families may need to travel substantial distances for appointments, procedures or treatment.
BC Children’s is also closely tied to pediatric cancer research through the Michael Cuccione Childhood Cancer Research Program and the hospital’s research institute. Work there includes precision medicine, early-phase clinical trials and studies designed to reduce treatment toxicity or improve options for relapsed and difficult-to-treat cancers. The practical value of that research is easy to miss in a fundraising announcement. For families, however, it can mean a more targeted therapy, access to an experimental option when standard treatment fails, or a better chance of avoiding serious long-term side effects after survival.
A $250,000 Bet on Stopping Metastatic Bone Cancer
The research portion of Hyundai’s B.C. commitment is a $250,000 award supporting Dr. Poul Sorensen, a distinguished scientist at the BC Cancer Research Centre, a University of British Columbia professor and a leader in childhood cancer research. His team is studying metastasis in osteosarcoma and Ewing sarcoma, two aggressive bone cancers affecting children and young adults. Metastatic disease—cancer that has spread beyond its original site—is one of the hardest problems in oncology and is strongly associated with poor outcomes.
Sorensen’s group has identified a protein involved in driving metastatic behaviour in these cancers. With the new funding, the team plans to test whether targeting that vulnerability with a clinically validated compound can make tumour cells more sensitive to lower doses of chemotherapy. The stated goal is to build a preclinical evidence package strong enough to support movement toward a clinical trial. That is an important middle step in cancer research: promising laboratory findings do not help patients until researchers can demonstrate enough safety and biological rationale to justify testing a treatment strategy in people.
Connor Bedard and the Handprint Tradition Add Visibility
The 2026 B.C. event also brought in North Vancouver native Connor Bedard, the Chicago Blackhawks star who serves as a Hyundai Canada brand ambassador. Bedard joined children and families at the Handprint Ceremony, a recurring Hope on Wheels tradition in which young cancer patients place painted handprints on a Hyundai vehicle. The ritual is simple, but its purpose is deliberate: it turns a corporate funding announcement into something visibly connected to the children the program is meant to support.
Bedard’s involvement adds considerable public reach, particularly among young hockey fans. Yet the event is most meaningful when the celebrity appearance stays secondary to the patients. The handprints, family stories and presence of hospital ambassadors create a reminder that pediatric cancer care is not only about survival statistics or laboratory breakthroughs. It is also about keeping childhood visible during treatment. Hyundai used the same handprint format in B.C. during the program’s first Canadian year, making the ceremony a recurring part of the initiative rather than a one-time promotional gesture.
The Dealer Network Turns Vehicle Sales Into a National Funding Stream
Hyundai Hope on Wheels is structured so that its fundraising mechanism is tied directly to the company’s core business. A portion of every new Hyundai sold in Canada supports the program, and Hyundai says its network of more than 225 dealers is participating in the 2026 effort. The company has committed more than $4.1 million this year to pediatric cancer initiatives, while its national program information identifies 16 Canadian pediatric oncology centres as being impacted by the funding.
That model spreads participation across the country instead of relying on a handful of large corporate gifts. A dealership in one community may be far from a major pediatric hospital, but vehicle sales still contribute to a national pool that can support care, research or family assistance. It also gives the charitable initiative a recurring funding mechanism rather than limiting support to occasional campaigns. For hospitals and researchers, longer-term relationships can be particularly valuable because laboratory programs, clinical trials, specialist infrastructure and survivorship initiatives often need sustained financing before their full impact can be measured.
Clinical Trials and Travel Support Are a Major Part of the $4.1 Million Plan
Hyundai’s national 2026 commitment goes beyond hospital grants. Of the more than $4.1 million pledged, $1.15 million has been allocated to initiatives for children with hard-to-treat cancers and the systems that help them reach clinical trials. The announced allocation includes $400,000 for trials investigating new treatments and $750,000 for STEP-1, a national program designed to reduce the financial burden of travelling for academic early-phase pediatric cancer trials.
The access problem is significant because specialized phase I and II studies are often available only at a small number of centres. STEP-1 provides upfront financial and logistical travel support, and its national expansion includes BC Children’s Hospital, SickKids and CHU Sainte-Justine. The importance of continuing that work is reinforced by federal data: approximately 1,000 Canadian children under 15 are diagnosed with cancer each year, while five-year survival has surpassed 86%. Those gains are closely associated with decades of scientific and treatment advances, including discoveries generated through clinical research. Better survival makes access to the next generation of trials—not simply funding research—part of the challenge ahead.
Year Two Shows a Shift From Donations to a Broader Cancer Ecosystem
Hyundai Hope on Wheels launched in Canada in 2025, when the company committed more than $4 million nationally and presented BC Children’s Hospital Foundation with a $250,000 donation. In 2026, the national commitment has risen above $4.1 million, but the more notable change is how the money is being distributed. In B.C., the direct hospital contribution is $100,000 while a separate $250,000 research award flows through the new C17 partnership. Nationally, additional funding is being directed toward research competitions, clinical trials and assistance for families travelling to specialized treatment.
That evolution suggests the Canadian program is moving from a straightforward hospital-donation model toward a broader pediatric cancer ecosystem. Care at the bedside still matters, but so do research pipelines, trial infrastructure, geographic access and survivorship. The C17 partnership is particularly significant because it connects Hyundai’s funding with Canada’s national pediatric hematology and oncology network and its structured research-grant process. For families, much of that work is less visible than a cheque presentation, but potentially more durable: support can touch multiple stages of the cancer journey, from diagnosis and experimental treatment to recovery and long-term care.
